Category: Covidien
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in June issue of Radiology, show that the treatment is safe and effective for certain patients, according to the company.
Covidien (NYSE:COV) subsidiary ev3 Inc. is touting the results of a pivotal trial of its Pipeline aneurysm embolization device, showing that the technology "offers a reasonably safe and effective treatment of large or giant intracranial internal carotid artery aneurysms."
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Covidien's doubling down in emerging markets yet again, looking to invest in Brazil, South Africa and Mexico and other high-growth regions in hopes of hitting $2 billion in emerging market revenue "as soon as possible."
Medical device giant Covidien is doubling down on emerging markets, expanding an investment program that the company had, at one point, thought would be over by the end of 2013.
Welcome to the latest edition of the MassDevice.com's D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
Fluid management device maker Cheetah Medical shakes up its C-suite and pulls in a $14.5 million financing round.
Cheetah Medical shook up the C-suite this week, added a new CEO and a new medical chief – plus $14.5 million to the fluid management device maker's coffers.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in Google searches for the last 30 days.
During the last month the medtech titans were flush with news from conferences, court rooms and Wall Street.
Masimo offers $1 million to any hospital that proves that its Masimo SET pulse oximeters are less accurate that Covidien's Nellcor devices.
